Albireo Pharma, Inc.
ALBO · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $380,521 | $388,958 | $578,105 | $449,264 |
| - Cash | $222,476 | $180,971 | $216,655 | $248,107 |
| + Debt | $0 | $10,158 | $10,080 | $10,004 |
| Enterprise Value | $158,045 | $218,145 | $371,530 | $211,161 |
| Revenue | $9,832 | $8,206 | $6,832 | $32,521 |
| % Growth | 19.8% | 20.1% | -79% | – |
| Gross Profit | $9,220 | $7,430 | $6,598 | $31,596 |
| % Margin | 93.8% | 90.5% | 96.6% | 97.2% |
| EBITDA | -$35,146 | -$37,119 | -$39,444 | $8,437 |
| % Margin | -357.5% | -452.3% | -577.3% | 25.9% |
| Net Income | -$38,413 | -$42,695 | -$45,310 | -$10,962 |
| % Margin | -390.7% | -520.3% | -663.2% | -33.7% |
| EPS Diluted | -1.95 | -2.18 | -2.34 | -0.57 |
| % Growth | 10.6% | 6.8% | -310.5% | – |
| Operating Cash Flow | -$29,630 | -$36,392 | -$35,409 | -$13,891 |
| Capital Expenditures | -$40 | -$685 | -$235 | -$279 |
| Free Cash Flow | -$29,670 | -$37,077 | -$35,644 | -$14,170 |